Impel NeuroPharma Inc.

IMPL 4 | $0.2411 -77.19% 860K

(0.0% 1d) (0.0% 1m) (-76.5% 1y) (0.0% 2d) (10.1% 3d) (0.0% 7d) (-28.63% volume)
Earnings Calendar: 2024-03-22
Market Cap: $ 5,762,297
https://impelnp.com
Sec Filling | Patents | n/a employees

(US) Impel NeuroPharma, Inc. is a late-stage pharmaceutical company focused on utilizing its proprietary technology to develop and commercialize transformative therapies for people suffering from diseases with high unmet needs, with an initial focus on diseases of the CNS. The Company’s strategy is to rapidly advance its product candidate pipeline that pairs its proprietary Precision Olfactory Delivery (POD®) system with well-established therapeutics, including TRUDHESA™ for the acute treatment of migraine, INP105 for the acute treatment of agitation and aggression in patients with autism, and INP107 for OFF episodes in Parkinson’s disease.

parkinson treatment

add to watch list Paper trade email alert is off

Prometheus Biosciences Inc

RXDX | $199.92 0.02% 1.9M

Professional, Scientific, and T...

(0.0% 1d) (0.0% 1m) (3.1% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-47.11% volume)
Earnings Calendar: 2023-08-09
Market Cap: $ 9,558,822,541
https://www.prometheusbiosciences.com
Sec Filling | Patents | n/a employees

Prometheus Biosciences, Inc. is a biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment and diagnosis of IBD. The company's precision medicine platform, Prometheus360, combines proprietary bioinformatics discovery methods with one of the world's largest gastrointestinal bioinformatics databases to identify novel therapeutic targets and develop therapeutic candidates to engage those targets. Prometheus is headquartered in San Diego, CA.

diagnostics gastrointestinal treatment

add to watch list Paper trade email alert is off

VectivBio Holding AG

VECT | $16.85 0.12% 130K

Professional, Scientific, and T...

(0.0% 1d) (0.0% 1m) (77.4% 1y) (0.0% 2d) (0.2% 3d) (0.0% 7d) (-48.24% volume)
Earnings Calendar:
Market Cap: $ 1,057,156,615
https://vectivbio.com
Sec Filling | Patents | 32 employees

VectivBio is a global, clinical-stage biotechnology company focused on the discovery, development and commercialization of innovative treatments for severe rare conditions with high unmet medical need. The company is committed to pursuing product candidates with a clear mechanism of action and the potential to meaningfully transform and improve the lives of patients and their families. VectivBio’s product candidate, apraglutide, is a next-generation GLP-2 analog being developed as a differentiated therapeutic for a range of rare gastrointestinal (GI) diseases. Apraglutide is currently being evaluated in a global phase 3 clinical trial as a once-weekly treatment for short bowel syndrome with intestinal failure (SBS-IF).

msa gastrointestinal treatment

add to watch list Paper trade email alert is off

Biomea Fusion Inc

BMEA | $10.87 -2.6% -2.67% 1.3M

Professional, Scientific, and T...

(0.0% 1d) (-24.3% 1m) (-59.2% 1y) (0.0% 2d) (0.0% 3d) (-4.5% 7d) (-13.61% volume)
Earnings Calendar: 2023-11-06
Market Cap: $ 390,117,343
https://www.biomeafusion.com
Sec Filling | Patents | 12 employees

Biomea Fusion, Inc. operates as a biopharmaceutical company. The Company focuseS on the discovery, development, and commercialization of irreversible small molecules to treat patients with genetically defined cancers. Biomea Fusion serves customers in the United States.

genetic cancer msa

add to watch list Paper trade email alert is off

Werewolf Therapeutics Inc

HOWL | $5.91 0.68% 0.68% 120K

Professional, Scientific, and T...

(0.0% 1d) (-3.9% 1m) (142.6% 1y) (0.0% 2d) (0.5% 3d) (6.9% 7d) (-70.97% volume)
Earnings Calendar: 2023-11-09
Market Cap: $ 256,182,915
https://werewolftx.com
Sec Filling | Patents | n/a employees

Werewolf Therapeutics, Inc. is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. The company is leveraging its proprietary PREDATOR™ platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE™ molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. Its most advanced product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2), and Interleukin-12 (IL-12) INDUKINE molecules for the treatment of solid tumors.The company is continuing preclinical studies for both WTX-124 and WTX-330 and expect to advance each candidate in multiple tumor types as a single agent and in combination with an immune checkpoint inhibitor.

cancer immunotherapy msa treatment

add to watch list Paper trade email alert is off

Finch Therapeutics Group Inc

FNCH | $2.205 -6.57% -7.03% 30K

Professional, Scientific, and T...

(0.0% 1d) (-8.0% 1m) (-79.0% 1y) (0.0% 2d) (0.0% 3d) (12.2% 7d) (-81.77% volume)
Earnings Calendar: 2023-03-30
Market Cap: $ 3,540,707
https://finchtherapeutics.com
Sec Filling | Patents | n/a employees

Finch Therapeutics is a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs. With the capabilities to develop both complete and targeted microbiome therapeutics, Finch is advancing a rich pipeline of candidates designed to address a wide range of unmet medical needs. Finch’s lead candidate, CP101, is in late-stage clinical development for the prevention of recurrent C. difficile infection (CDI), and has received Breakthrough Therapy and Fast Track designations from the U.S. Food and Drug Administration. In June 2020, Finch announced that CP101 met its primary efficacy endpoint in PRISM3, the first of two pivotal trials to support the development of CP101 for the prevention of recurrent CDI. Finch plans to initiate a Phase 3 trial, referred to as PRISM4, as its second pivotal trial of CP101 for recurrent CDI. Finch is also developing CP101 for the treatment of chronic hepatitis B virus, and FIN-211 for the treatment of the gastrointestinal and behavioral symptoms of autism spectrum disorder. In partnership with Takeda, Finch is advancing FIN-524 and FIN-525 for the treatment of ulcerative colitis and Crohn’s disease, respectively.

hepatitis gastrointestinal treatment injection

add to watch list Paper trade email alert is off

Gain Therapeutics Inc

GANX | $3.155 0.16% 0.16% 71K

Professional, Scientific, and T...

(0.0% 1d) (-25.4% 1m) (-36.4% 1y) (0.0% 2d) (0.0% 3d) (2.9% 7d) (-27.65% volume)
Earnings Calendar: 2024-03-21
Market Cap: $ 51,173,182
https://www.gaintherapeutics.com
Sec Filling | Patents | 27 employees

Gain Therapeutics, Inc. is redefining drug discovery with its See-Tx™ target identification platform. By identifying and optimizing allosteric binding sites that have never before been targeted, Gain is unlocking new treatment options for difficult-to-treat disorders characterized by protein misfolding. In July 2020, Gain Therapeutics, Inc. completed a share exchange with Gain Therapeutics, SA, a Swiss corporation, whereby GT Gain Therapeutics SA became a wholly owned subsidiary of Gain Therapeutics, Inc.

parkinson drug discovery treatment optical

add to watch list Paper trade email alert is off

Recursion Pharmaceuticals Inc - Class A

RXRX | $7.36 -0.54% -0.54% 3.9M

Professional, Scientific, and T...

(0.0% 1d) (-33.2% 1m) (36.0% 1y) (0.0% 2d) (-0.9% 3d) (-11.9% 7d) (-18.4% volume)
Earnings Calendar: 2024-02-26
Market Cap: $ 1,671,775,431
https://www.recursionpharma.com
Sec Filling | Patents | n/a employees

Recursion is a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery. Central to its mission is the Recursion Operating System, or Recursion OS, that combines an advanced infrastructure layer to generate what Recursion believes is one of the world's largest and fastest-growing proprietary biological and chemical datasets and the Recursion Map, a suite of custom software, algorithms, and machine learning tools that the company uses to explore foundational biology unconstrained by human bias and navigate to new biological insights which may accelerate its programs. biotechnology company scaling more like a technology company.

drug discovery machine learning

add to watch list Paper trade email alert is off

Akoya Biosciences Inc

AKYA | $3.81 -1.04% -1.05% 170K

Professional, Scientific, and T...

(0.0% 1d) (-21.0% 1m) (-44.3% 1y) (0.0% 2d) (0.0% 3d) (-0.7% 7d) (100.14% volume)
Earnings Calendar: 2024-03-04
Market Cap: $ 187,226,185
https://www.akoyabio.com
Sec Filling | Patents | n/a employees

As The Spatial Biology Company®, Akoya Biosciences’ mission is to bring context to the world of biology and human health through the power of spatial phenotyping. The company offers comprehensive single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and treatment response. Akoya offers two distinct solutions, the CODEX® and Phenoptics™ platforms, to serve the diverse needs of researchers across discovery, translational and clinical research.

t-cell treatment ceiling

add to watch list Paper trade email alert is off

Reneo Pharmaceuticals Inc

RPHM | $1.74 -1.14% -1.15% 83K

Professional, Scientific, and T...

(0.0% 1d) (6.6% 1m) (-81.9% 1y) (0.0% 2d) (0.0% 3d) (6.6% 7d) (616.69% volume)
Earnings Calendar: 2024-03-27
Market Cap: $ 58,152,206
https://reneopharma.com
Sec Filling | Patents | 32 employees

Reneo is a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP). Reneo is developing REN001 to modulate genes critical to metabolism and generation of ATP, which is the primary source of energy for cellular processes. REN001 has been shown to increase transcription of genes involved in mitochondrial function and increase fatty acid oxidation, and may increase production of new mitochondria.

energy renewable genetic metabolic

add to watch list Paper trade email alert is off

Instil Bio Inc

TIL | $10.53 1.15% 1.14% 9.9K

Professional, Scientific, and T...

(0.0% 1d) (-13.3% 1m) (1528.2% 1y) (0.0% 2d) (0.0% 3d) (1.4% 7d) (-6.65% volume)
Earnings Calendar: 2023-11-13
Market Cap: $ 68,486,204
https://instilbio.com
Sec Filling | Patents | 412 employees

(US) Instil Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing an innovative cell therapy pipeline of autologous TIL therapies for the treatment of patients with cancer.

cancer t-cell treatment ceiling

add to watch list Paper trade email alert is off

TransCode Therapeutics Inc

RNAZ | $0.49 -2.39% -2.45% 110K

Professional, Scientific, and T...

(0.0% 1d) (-28.6% 1m) (-92.9% 1y) (0.0% 2d) (0.0% 3d) (-6.8% 7d) (31.17% volume)
Earnings Calendar: 2022-11-14
Market Cap: $ 2,845,946
https://www.transcodetherapeutics.com
Sec Filling | Patents | 2021 employees

TransCode Therapeutics is an emerging RNA oncology company created to realize its belief that cancer can be defeated through the intelligent design of RNA therapeutics. This belief is based on a new approach to address what TransCode believes has been the most intractable challenge in RNA therapeutics: delivering an oligonucleotide to its target before the body’s immune system can attack and dismantle it. Its platform of investigational drug candidates is dedicated to improving patient outcomes encompassing a variety of tumor types. TransCode’s lead therapeutic candidate, TTX-MC138, is focused on treating metastatic cancer, which TransCode believes has the potential to produce regression without recurrence in a range of cancers, including breast, pancreatic, ovarian and colon cancer, glioblastomas and others. TransCode anticipates submitting an IND, in the second half of 2021 to support initiation of a Phase 0 clinical study with TTX-MC138.

cancer pancreatic glioblastoma

add to watch list Paper trade email alert is off

Design Therapeutics Inc

DSGN | $3.695 -1.2% -1.22% 390K

Professional, Scientific, and T...

(0.0% 1d) (27.2% 1m) (-34.0% 1y) (0.0% 2d) (0.0% 3d) (-2.6% 7d) (-54.63% volume)
Earnings Calendar: 2023-11-02
Market Cap: $ 208,746,331
https://www.designtx.com
Sec Filling | Patents | n/a employees

Design Therapeutics is a biotechnology company developing a new class of therapies based on a platform of gene targeted chimera (GeneTAC™) small molecules. The company’s lead program is focused on the treatment of Friedreich ataxia, followed by a program in myotonic dystrophy type-1 and discovery efforts for multiple other serious degenerative disorders caused by nucleotide repeat expansions.

treatment

add to watch list Paper trade email alert is off